These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 6405420)
1. Sedative and electroencephalographic actions of erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA): relationship to inhibition of brain adenosine deaminase. Mendelson WB; Kuruvilla A; Watlington T; Goehl K; Paul SM; Skolnick P Psychopharmacology (Berl); 1983; 79(2-3):126-9. PubMed ID: 6405420 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice. Lambe CU; Nelson DJ Biochem Pharmacol; 1982 Feb; 31(4):535-9. PubMed ID: 7066021 [TBL] [Abstract][Full Text] [Related]
3. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. Antonini I; Cristalli G; Franchetti P; Grifantini M; Martelli S; Lupidi G; Riva F J Med Chem; 1984 Mar; 27(3):274-8. PubMed ID: 6699873 [TBL] [Abstract][Full Text] [Related]
4. Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. Cristalli G; Franchetti P; Grifantini M; Vittori S; Lupidi G; Riva F; Bordoni T; Geroni C; Verini MA J Med Chem; 1988 Feb; 31(2):390-3. PubMed ID: 3339608 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA). Lum CT; Schmidtke JR; Sutherland DE; Najarian JS Clin Immunol Immunopathol; 1978 Jul; 10(3):258-61. PubMed ID: 307473 [No Abstract] [Full Text] [Related]
6. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition. Bessodes M; Bastian G; Abushanab E; Panzica RP; Berman SF; Marcaccio EJ; Chen SF; Stoeckler JD; Parks RE Biochem Pharmacol; 1982 Mar; 31(5):879-82. PubMed ID: 7082355 [No Abstract] [Full Text] [Related]
7. Inhibition of PHA and NaI04 mitogenesis by the adenosine deaminase inhibitors erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 2-deoxycoformycin (2-dCF). Lum CT; Sutherland DE; Najarian JS Clin Immunol Immunopathol; 1979 Apr; 12(4):453-9. PubMed ID: 222523 [No Abstract] [Full Text] [Related]
8. Inhibition of adenosine deaminase from several sources by deaza derivatives of adenosine and EHNA. Lupidi G; Cristalli G; Marmocchi F; Riva F; Grifantini M J Enzyme Inhib; 1985; 1(1):67-75. PubMed ID: 3916912 [TBL] [Abstract][Full Text] [Related]
9. The protonated form of 1-N6-etheno-[erythro-9-(2-hydroxy-3-nonyl)] adenine is identified at the active site of adenosine deaminase. Caiolfa VR; Gill D; Parola AH FEBS Lett; 1990 Jan; 260(1):19-22. PubMed ID: 2153576 [TBL] [Abstract][Full Text] [Related]
10. Effects of the chiral isomers of erythro- and threo-9-(2-hydroxy-3-nonyl)adenine on purine metabolism in sarcoma 180 cells. Chen SF; Stoeckler JD; Choi HS; Burgess FW; Marcaccio EJ; Steen PA; Berman SF; Parks RE; Panzica RP; Abushanab E Biochem Pharmacol; 1982 Dec; 31(24):3955-60. PubMed ID: 7159473 [TBL] [Abstract][Full Text] [Related]
11. Optimization of the local inhibition of intestinal adenosine deaminase (ADA) by erythro-9-(2-hydroxy-3-nonyl)adenine: enhanced oral delivery of an ADA-activated prodrug for anti-HIV therapy. Singhal D; Anderson BD J Pharm Sci; 1998 May; 87(5):578-85. PubMed ID: 9572908 [TBL] [Abstract][Full Text] [Related]
12. Kinetics of inhibition of calf intestinal adenosine deaminase by (+)- and (-)-erythro-9-(2-hydroxy-3-nonyl)adenine. Porter DJ; Abushanab E Biochemistry; 1992 Sep; 31(35):8216-20. PubMed ID: 1525161 [TBL] [Abstract][Full Text] [Related]
14. Erythro-9-(2-hydroxy-3-nonyl)adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues. North TW; Cohen SS Proc Natl Acad Sci U S A; 1978 Oct; 75(10):4684-8. PubMed ID: 216993 [TBL] [Abstract][Full Text] [Related]
15. Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. Cristalli G; Eleuteri A; Franchetti P; Grifantini M; Vittori S; Lupidi G J Med Chem; 1991 Mar; 34(3):1187-92. PubMed ID: 2002459 [TBL] [Abstract][Full Text] [Related]
16. Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolites of (+)-erythro-9-(2S-hydroxy-3R-nonyl)adenine. Vargeese C; Sarma MS; Pragnacharyulu PV; Abushanab E; Li SY; Stoeckler JD J Med Chem; 1994 Oct; 37(22):3844-9. PubMed ID: 7966142 [TBL] [Abstract][Full Text] [Related]
17. Adenosine deaminase inhibitors. Conversion of a single chiral synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenines. Bastian G; Bessodes M; Panzica RP; Abushanab E; Chen SF; Stoeckler JD; Parks RE J Med Chem; 1981 Dec; 24(12):1383-5. PubMed ID: 7310814 [No Abstract] [Full Text] [Related]
18. Adenosine uptake and deamination regulate tonic A2a receptor facilitation of evoked [3H]acetylcholine release from the rat motor nerve terminals. Correia-de-Sá P; Ribeiro JA Neuroscience; 1996 Jul; 73(1):85-92. PubMed ID: 8783232 [TBL] [Abstract][Full Text] [Related]
19. Identification of the bioactive enantiomer of erythro-3-(adenin-9-yl)-2-nonanol (EHNA), a semi-tight binding inhibitor of adenosine deaminase. Baker DC; Hanvey JC; Hawkins LD; Murphy J Biochem Pharmacol; 1981 May; 30(10):1159-61. PubMed ID: 7259798 [No Abstract] [Full Text] [Related]
20. Modifications of flexible nonyl chain and nucleobase head group of (+)-erythro-9-(2's-hydroxy-3's-nonyl)adenine [(+)-EHNA] as adenosine deaminase inhibitors. Kandalkar SR; Ramaiah PA; Joshi M; Wavhal A; Waman Y; Raje AA; Tambe A; Ansari S; De S; Palle VP; Mookhtiar KA; Deshpande AM; Barawkar DA Bioorg Med Chem; 2017 Oct; 25(20):5799-5819. PubMed ID: 28951094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]